Gastric cancer is the fifth most common cancer diagnosed and the third most common cause of cancer death globally (1). For patients with operable gastric cancer, complete surgical resection offers the only realistic chance of cure, however up to half of patients treated with optimal multimodality therapy will relapse following potentially curative surgery (2-5). Advanced recurrent or metastatic gastric cancer is associated with a median overall survival of less than 1 year for patients in clinical trials, and only incremental survival benefits have been made with second line therapies (6-12). The anti-HER2 monoclonal antibody trastuzumab and the anti-VEGFR2 antibody ramucirumab represent the totality of currently licensed targeted therapies available for patients with advanced gastric cancer (11-13). Hence, development of alternative treatment options is strongly encouraged.

Regorafenib is a small molecule inhibitor of multiple intracellular tyrosine kinases including angiogenesis related pathways (VEGFR1 and 2), stromal factors (PDGFβ) and oncogenic drivers (BRAF, RET, KIT) (14). Treatment with regorafenib is associated with survival benefits in metastatic colorectal, gastrointestinal stromal and hepatocellular cancers (15-17). The recently published results of the INTEGRATE study, which evaluated the use of regorafenib in previously treated gastric cancer patients, suggest potential efficacy for regorafenib also in this disease (18). In INTEGRATE, patients were recruited from sites in Australia, New Zealand, Canada and Korea and randomized in a 2:1 ratio to either regorafenib (160 mg daily orally, 21 days on with 7 days off schedule) or placebo. The primary endpoint of the trial was progression free survival. One hundred and forty seven patients were treated on study, and the primary outcome measure demonstrated that patients treated with regorafenib had statistically significantly improved progression free survival compared to patients who received placebo [2.6 vs. 0.9 months (HR 0.40; 95% CI, 0.28–0.59; stratified log-rank P<0.001)]. Consistent with the effects of regorafenib in chemorefractory metastatic colorectal cancer, most of the benefit of regorafenib appeared to be in disease control. Radiological responses were infrequent in regorafenib treated patients; 3 of 100 patients had a RECIST response (3%, 95% CI, 1–9%). Toxicity was as expected; rates of serious adverse events were 32% vs. 18% in patients treated on the experimental and control arms respectively. The magnitude of benefit derived from regorafenib appeared to be much higher in Korean patients than in non-Asian patients (HR 0.61 non-Asian patients vs. 0.12 for Korean patients, P value for interaction <0.001). This difference remained even when corrected for other pre-specified covariates and interaction terms. Based on the results of the INTEGRATE trial, regorafenib will be assessed in a randomized phase III trial (INTEGRATE II NCT02773524).

The results of the INTEGRATE trial are encouraging, however a phase III trial is indicated in order to fully evaluate the potential benefits of regorafenib in this population. In particular, the progression free survival results in the control arm of INTEGRATE are poor (0.9 months) for a population containing 42% of
patients previously treated with only one prior line of chemotherapy (18). Furthermore, although the radiological response rate associated with regorafenib was low, this is unsurprising for an anti-angiogenic therapy. Despite similarly low radiological response rates in chemorefractory metastatic colorectal cancer patients, regorafenib was associated with a statistically significant improvement in overall survival in the CORRECT trial (15). Also encouraging is that since INTEGRATE was designed, inhibition of angiogenesis has been validated as a clinically useful target for patients with advanced gastric cancer; ramucirumab has become a standard of care in the second line setting, and the small molecule inhibitor apatinib has also been successful in a phase III randomized trial in China, with further confirmatory trials pending. However, as ramucirumab is now established as a standard of care, it is unknown how this may impact on the efficacy of regorafenib in the upcoming INTEGRATE II trial.

Preliminary biomarker analysis from INTEGRATE suggest that the benefit of regorafenib was comparable in patients with VEGF-A levels above and below the median (18). Validated biomarkers for anti-angiogenic therapy have been elusive; in a comprehensive translational analysis of the CORRECT trial the benefits of regorafenib were consistent across subgroups of patients ascertained using mutation status, plasma ctDNA concentration, and multiple plasma proteins (19). As many historic studies across tumour types examining circulating and tissue targets putatively associated with the efficacy of anti-angiogenic therapy have failed to consistently identify or validate any such biomarker, it is unlikely that further focus on angiogenesis related biomarkers will be fruitful in this setting (20-22). However, unlike bevacizumab and ramucirumab, regorafenib also targets intracellular drivers of angiogenesis and cell growth such as the FGFR family (14). Preclinical work in gastric and colorectal cancer cell lines demonstrates that FGFR2 amplified cells are sensitive to growth inhibition using to regorafenib at submicromolar concentrations (23). As up to 9% of gastric cancers demonstrate FGFR2 amplification and highly FGFR2 amplified cancers demonstrate oncogenic addiction to this pathway, it is possible to speculate that the activity of regorafenib in gastric cancer could relate to inhibition of intracellular tyrosine kinases in addition to antiangiogenic activity (24,25). However, VEGFR1 and VEGFR2 dysregulation have also been described in gastric cancer, and less commonly aberrations of RET and KIT, and it is therefore possible that any, or all, of these regorafenib targets could play a role in the responses of individual patients to this drug (24).

The ultimate role for regorafenib in the treatment of advanced gastric cancer will be determined by the results of the phase III randomized INTEGRATE II trial. However, it is possible that the divergent benefits of regorafenib in geographically defined subsets of patients could influence the overall outcome of INTEGRATE II. In gastric cancer, regional variation as a confounder of international randomised trial results has precedent, as this occurred in the AVAGAST study (21). Whether regorafenib can be combined with standard cytotoxic chemotherapy is being explored in two early stage studies; REPEAT is a phase Ib study which will examine the activity of regorafenib in combination with paclitaxel (NCT02406170) and a small phase II study which combines regorafenib with FOLFOX chemotherapy for previously untreated patients with gastric cancer is also underway (NCT01913639). Although multitargeted tyrosine kinase inhibitors in general have not been successful in conjunction with chemotherapy to date, proof of concept for efficacy of regorafenib as a single agent has already been demonstrated in INTEGRATE, and it is conceivable that additive benefit could be achieved in these studies. As patients with gastric cancer have limited treatment options, any addition to those currently available is very welcome.

Acknowledgements

Funding: The author acknowledges funding from the Royal Marsden/Institute of Cancer Research National Institute for Health Research Biomedical Research Centre (RM/ICR NIHR BRC).

Footnote

Conflicts of Interest: The author declares honoraria from Five Prime Therapeutics for advisory board participation and from Bristol Meyer-Squibb for honorarium for advisory role.

References

2. Cunningham D, Allum WH, Stenning SP, et al.


doi: 10.21037/tgh.2017.01.07

Cite this article as: Smyth EC. Regorafenib in gastric cancer. Transl Gastroenterol Hepatol 2017;2:16.